High prevalence and undertreatment of hypercholesterolaemia in participants in a public stroke prevention programme in Austria

Clinical Drug Investigation

Volumn 25, Issue 11, 2005, Pages 709-717

  Iglseder, Bernhard ^a   Moroder, Titus ^a   Staffen, Wolfgang ^a   Ladurner, Gunther ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; AUSTRIA; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; HEALTH CARE QUALITY; HEALTH PROGRAM; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STROKE; TREATMENT INDICATION;

EID: 27644471492     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525110-00004     Document Type: Article

References (35)

1. Mackay J, Mensah G, editors. Atlas of heart disease and stroke. Geneva: World Health Organisation, 2004 [online]. Available from URL: http://www.who.int/cardiovascular_diseases/resources/atlas/en/print.html [Accessed 2005 May 23]
2. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. BMJ 1991; 303: 276-82
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
4. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
5. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
6. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58
7. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischemic heart disease? BMJ 1994; 308: 367-72
8. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure, and stroke: 13 000 strokes in 450 000 people in 45 prospective cohorts. Lancet 1995; 346: 1647-53
9. Lindenstroem E, Boysen G, Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on the risk of cerebrovascular disease: The Copenhagen City Heart Study. BMJ 1994; 309: 11-5
10. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103: 387-92
11. Crouse III JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455-9
12. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81
13. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22
14. Chambless LE, Folsom AR, Clegg LX, et al. Carotid wall thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 478-87
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22
16. Di Napoli P, Taccardi AA, Oliver M, et al. Statins and stroke: evidence for cholesterol-independent effects. Eur Heart J 2002; 23: 1908-21
17. Iglseder B, Moroder T, Staffen W, et al. Inadequate management of cerebrovascular risk factors in participants of a public stroke prevention program in Austria. Eur J Neurol 2004; 11: 679-85
18. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III. JAMA 2001; 285: 2486-2497
19. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991; 22: 312-8
20. American Diabetes Association. New recommendations about the diagnosis and classification of diabetes mellitus. Diabetes Care 1997; 20: 1138-95
21. Mosca L, Jones WK, King KB, et al. Awareness, perception, and knowledge of heart disease risk and prevention among women in the United States. Arch Fam Med 2000; 9: 506-15
22. Kahl H, Hölling H, Kamtsiuris P. Inanspruchnahme von Früherkennungsuntersuchungen und Maßnahmen zur Gesundheitsfö rderung. Gesundheitswesen 1999; 61 Suppl. 2: 163-8
23. Meagher EA. Addressing cardiovascular disease in women: focus on dyslipidemia. J Am Board Fam Pract 2004; 17: 424-37
24. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross section survey. BMJ 2000; 321: 1322-5
25. Whincup PH, Emberson JR, Lennon L, et al. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart 2002; 88: 25-9
26. Oliver MF. Might treatment of hypercholesterolemia increase non-cardiac mortality? Lancet 1991; 337: 1529-31
27. Wallis E, Ramsay LE, Haq IU. Coronary and cardiovascular risk estimation: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000; 320: 671-6
28. Pickin DM, McCabe CJ, Ramsey LE. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999; 82: 325-32
29. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J 2001; 22 (9): 751-61
30. Ballesteros LC, Fernandez San Martin MI, Sanz Cuesta T, et al. The cost of inadequate prescriptions for hypolipidemic drugs. VICAF Group. Pharmacoeconomics 2001; 19: 513-22
31. Austrian Atherosclerosis Society (AAS). Cholesterinkonsensus 2000 [online]. Available from URL: www.aas.at [Accessed 2005 Aug 16]
32. Mantel-Teeuwisse AK, Verschuren WMM, Klungel OH, et al. Recent trends in (under)treatment of hypercholesterolemia in the Netherlands. Br J Clin Pharmacol 2004; 58: 310-6
33. Monkman D. Treating dyslipidaemia in primary care. BMJ 2000; 32: 1299-300
34. Denke MA. Cholesterol-lowering diets: a review of the evidence. Arch Intern Med 1995; 155: 17-26
35. Brunner E, Cohen D, Toon L. Cost effectiveness of cardiovascular disease prevention strategies: a perspective on EU food based dietary guidelines. Public Health Nutr 2001; 4: 711-5